[Skip to Navigation]
Sign In
Comment & Response
December 2018

BRAF V600E Mutation as a Negative Prognostic Determinant in Resected Colorectal Liver Metastases—Reply

Author Affiliations
  • 1Department of Surgery, Johns Hopkins University School of Medicine, Baltimore, Maryland
JAMA Surg. 2018;153(12):1163-1164. doi:10.1001/jamasurg.2018.3339

In Reply We thank Moretto et al for their interest in our study.1 As the authors correctly suspected, only a small fraction of the patient population (7 patients) received preoperative fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI); the introduction of this regimen is a fairly recent development that is not well represented in our cohort, which stretches back to 2000. Moreover, only 1 patient treated with FOLFOXIRI had a non-V600E BRAF mutation while the remaining 6 had V600E BRAF mutations, leaving little room for codon/point-specific stratification.1

Add or change institution
Limit 200 characters
Limit 25 characters
Conflicts of Interest Disclosure

Identify all potential conflicts of interest that might be relevant to your comment.

Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.

Err on the side of full disclosure.

If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.

Not all submitted comments are published. Please see our commenting policy for details.

Limit 140 characters
Limit 3600 characters or approximately 600 words
    ×